Business Context and Reporting Period
This Form 8-K Current Report for Gossamer Bio, Inc. (Nasdaq: GOSS) covers events occurring on September 16, 2026. The filing primarily addresses corporate governance changes, specifically the appointment of a new director, and details related compensatory arrangements and prior investment commitments.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and specific securities transactions related to a private placement.
- Director Cash Compensation: Annual retainer of $40,000 for Board service and $7,500 for Audit Committee service.
- Equity Compensation: Standard initial award amount and timing to be determined by the Board at a future date.
Material Changes
The primary material change reported is the appointment of Gregory A. Ciongoli as a Class III director and member of the Audit Committee, effective September 16, 2026. His term expires at the 2027 annual meeting of stockholders. Additionally, the filing references a 1-for-80 reverse stock split effectuated on September 10, 2026, which adjusts the share counts for securities previously agreed upon in a private placement transaction.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business operations. It does not disclose new risks or contingencies beyond the standard indemnification agreement entered into by the new director. The document notes that Mr. Ciongoli was a purchaser in the "2026 PIPE" private placement, with commitments to purchase pre-funded warrants and FDA approval warrants contingent on stockholder approval and specific pricing conditions.
Investor Verification Checklist
- Verify the status of stockholder approval required for the conversion of Mr. Ciongoli's pre-funded warrants into common stock.
- Confirm the final terms of the "2026 PIPE" transaction referenced in the August 21, 2026, Form 8-K.
- Monitor future Board determinations regarding the specific amount and timing of Mr. Ciongoli's initial equity award.
- Review the impact of the September 10, 2026, 1-for-80 reverse stock split on outstanding share counts and warrant exercise prices.